|
Jul 16
|
Cognition Therapeutics' Positive Clinical Data from Zervimesine (CT1812) Phase 2 Study in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at AAIC
|
|
Jul 11
|
Cognition Therapeutics, Inc. (CGTX) Retains Buy Rating on START Study Progress
|
|
Jul 1
|
Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer’s Disease Surpasses 50% Enrollment Target
|
|
Jun 28
|
We're A Little Worried About Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate
|
|
Jun 25
|
Cognition Therapeutics Provides Regulatory Update on Zervimesine (CT1812) in Alzheimer’s Disease and Dementia with Lewy Bodies (DLB)
|
|
May 28
|
Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Studying the Patient/Caregiver Lived Experience in Dementia with Lewy Bodies
|
|
May 9
|
Cognition announces outcomes from trial of zervimesine for geographic atrophy
|
|
May 9
|
Cognition Therapeutics Presented Data at Association for Research in Vision and Ophthalmology Showing Impact on Retinal Cell Health
|
|
May 8
|
Cognition Therapeutics Reports Topline Results Showing Oral Zervimesine (CT1812) Reduced Lesion Growth in Phase 2 Study in Geographic Atrophy
|
|
May 7
|
Cognition Therapeutics Reports Financial Results for the First Quarter 2025 and Provides Business Update
|
|
Oct 9
|
Cognition Therapeutics Inc (CGTX) Q2 2024 Earnings Call Highlights: Promising Alzheimer's Trial ...
|
|
Jul 30
|
Cognition Therapeutics’ stock dips 43% following trial results for Alzheimer’s candidate
|
|
Jul 29
|
Cognition Therapeutics’ Proof-of-Concept Phase 2 SHINE Trial Demonstrates Consistent Improvement in Cognitive Outcomes with Once-Daily Oral CT1812 in Mild-to-Moderate Alzheimer’s Patients
|
|
Jul 26
|
Cognition Therapeutics to Host Investor Webcast to Discuss Results from Proof-of-Concept Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease at 8:30am ET on Monday July 29, 2024
|
|
Mar 15
|
Cognition Therapeutics to Report Fourth Quarter and Full Year 2023 Results
|
|
Mar 14
|
Cognition Therapeutics Announces Closing of $11.5 Million Public Offering of Common Stock
|
|
Jan 16
|
Here's Why We're Watching Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Situation
|
|
Jan 4
|
Cognition Therapeutics CEO Issues Letter to Shareholders
|
|
Nov 16
|
Cognition Therapeutics Releases New Episode of “Conversations” Podcast Recorded at CTAD with Quantitative EEG Experts, Drs Willem de Haan and Philip Scheltens
|
|
Nov 15
|
Cognition Therapeutics Presents Preclinical Data Identifying Pathways Impacted by Sigma-2 Receptor Modulators in Alzheimer’s and Parkinson’s Diseases
|